EUVIMEDEUVIMED entdecken
Open Access

GRP78 Drives NSCLC Stemness and EMT via a SIX1/β‐Catenin Signaling Axis

Guoping Tong, Huanyu Qi iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Guoping Tong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Tumor Internal Medicine, Chinese Academy of Medical Sciences Cancer Hospital Shanxi Hospital, Shanxi Cancer Hospital, T…. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Carcinoma, Non-Small-Cell Lung, beta Catenin, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shanxi Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐small cell lung cancer (NSCLC) exhibits stem‐like characteristics that drive tumor aggressiveness and treatment resistance. The molecular chaperone Glucose‐Regulated Protein 78 (GRP78) is substantially elevated in NSCLC compared to normal tissues and cell lines. In clinical samples, GRP78 protein levels correlated with advanced tumor stage and lymph node metastasis. Pharmacological inhibition of GRP78 using BAPTA‐AM and GRP78‐IN‐3 significantly suppressed NSCLC cell viability while promoting apoptosis. The inhibitors effectively attenuated cell migration by downregulating matrix metalloproteinases and reversed epithelial‐mesenchymal transition by modulating key cadherin expression profiles. Importantly, GRP78 inhibition substantially reduced cancer stem cell markers and impaired spheroid formation capability. Genetic knockdown of GRP78 in A549 and H1975 cells recapitulated the effects of pharmacological inhibition, reducing cell migration, reversing EMT, attenuating stemness, and suppressing β‐catenin signaling. Conversely, GRP78 overexpression in A549 and H1975 cells induced opposite effects, promoting mesenchymal markers, enhancing stemness proteins, and increasing spheroid size. Mechanistic studies revealed that this anti‐tumor activity operates through suppression of β‐catenin signaling mediated by SIX1, as evidenced by SIX1‐overexpression rescue experiments. These findings demonstrate that GRP78 acts as a key regulator of NSCLC stemness and metastatic potential by coordinating epithelial plasticity and stemness pathways, positioning it as a promising therapeutic target for NSCLC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionCarcinoma, Non-Small-Cell Lungbeta CateninLung NeoplasmsNeoplastic Stem CellsHeat-Shock ProteinsHomeodomain ProteinsHumansEndoplasmic Reticulum Chaperone BiPSignal TransductionCell Line, TumorCell MovementApoptosis

Stichwörter der Autor:innen

EMTGRP78NSCLCSIX1stemnessβ‐catenin

Substanzen

Endoplasmic Reticulum Chaperone BiPHSPA5 protein, humanbeta CateninHeat-Shock ProteinsHomeodomain ProteinsCTNNB1 protein, human

Autor:innen und Institutionen

  • Department of Respiratory and Tumor Internal Medicine, Chinese Academy of Medical Sciences Cancer Hospital Shanxi Hospital, Shanxi Cancer Hospital, Taiyuan City, Shanxi Province, China.
  • Department of Bone and Soft Tissue Tumor Oncology, Chinese Academy of Medical Sciences Cancer Hospital Shanxi Hospital, Shanxi Cancer Hospital, Taiyuan City, Shanxi Province, China.

ORCID-Profile: Huanyu Qi

Förderung

  • Shanxi Cancer Hospital

Zitieren

APA

Tong, G., & Qi, H. (2026). GRP78 Drives NSCLC Stemness and EMT via a SIX1/β‐Catenin Signaling Axis. Drug Development Research. https://doi.org/10.1002/ddr.70359

Vancouver

Tong G, Qi H. GRP78 Drives NSCLC Stemness and EMT via a SIX1/β‐Catenin Signaling Axis. Drug Development Research. 2026. doi:10.1002/ddr.70359

BibTeX
@article{Tong2026,
  author = {Tong, Guoping and Qi, Huanyu},
  title = {GRP78 Drives NSCLC Stemness and EMT via a SIX1/β‐Catenin Signaling Axis},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70359}
}
Kostenlos starten →